Dysfunction of the TP53 (p53) gene occurs in most if not all human malignancies. Two
principal mechanisms are responsible for this dysfunction; mutation and downregulation of …

Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized
by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis …

Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …

Mutational signature analysis is commonly performed in cancer genomic studies. Here, we
present SigProfilerExtractor, an automated tool for de novo extraction of mutational …

Small cell lung cancer (SCLC) is a type of neuroendocrine tumor with high malignancy and
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …

Background Multiple lines of evidence have demonstrated that circular RNAs (circRNAs)
play oncogenic or tumor-suppressive roles in various human cancers. Nevertheless, the …

The MYC transcription factor, encoded by the c‐MYC proto‐oncogene, is activated by
growth‐promoting signals, and is a key regulator of biosynthetic and metabolic pathways …

Small cell lung cancer (SCLC) is a rapidly growing, highly metastatic, and relatively immune-
cold lung cancer subtype. Historically viewed in the laboratory and clinic as a single …

Progress in the overall treatment of small-cell lung cancer (SCLC) has moved at a slower
pace than non–small-cell lung cancer. In fact, the standard treatment regimen for limited …

Simple Summary Cancer is largely caused by genetic alterations such as mutations in a
group of genes known as cancer driver genes. Many of the key advances in cancer …